Tag: nasdaq:nlnk

November 12, 2019

NewLink Genetics Receives European Commission Grant of Conditional Marketing Approval for V920

The European Commission has granted a conditional marketing authorization to ERVEBO, an investigational V920 Ebola Zaire vaccine.
October 6, 2019

5 Top NASDAQ Biotech and Pharma Stocks: Constellation Leads

Which biotech and pharma stocks were on the rise last week? We list the top gainers and what may have...
September 30, 2019

NewLink Genetics and Lumos Pharma to Form Biopharma Company

The agreement is expected to close in Q1 2020. NewLink Genetics will change its name to Lumos Pharma and its...
September 18, 2019

NewLink Genetics Receives FDA Acceptance for Partnered Biologics License Application

NewLink Genetics (NASDAQ:NLNK) has announced that the US Food and Drug Administration has accepted Merck’s (NYSE:MRK)’s Biologics License Application and...
May 26, 2019

5 Top Weekly NASDAQ Biotech and Pharma Stocks: Sesen Bio Up 40 Percent

Which NASDAQ biotech and pharma stocks were up last week? We examine the top five gainers and what may have...
April 2, 2019

NewLink Genetics Presents Phase 2 Results for NLG207 in Ovarian Cancer at AACR 2019

NewLink Genetics (NASDAQ:NLNK) has announced results from its Phase 2 study of NLG207, a nanoparticle of the topoisomerase 1 inhibitor...
November 15, 2018

NewLink Genetics Announces Merck Has Begun Rolling Submission of Licensure Application for Ebola vaccine V920

NewLink Genetics (NASDAQ:NLNK) reported today that Merck has begun the submission of a rolling Biologics License Application (BLA) to the U.S. Food and...